[
    "{\"step_by_step_thinking\": \"Based on the provided documents, DNX-2401 was indeed tested for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG). Document [1] mentions a clinical Phase I trial for newly diagnosed pediatric DIPG using DNX-2401. Document [4] also describes a single-center, dose-escalation study of DNX-2401 in patients with newly diagnosed DIPG. Therefore, the answer is A. yes.\", \"answer_choice\": \"A\"}"
]